Omega Therapeutics
Omega Therapeutics was a Cambridge-based clinical-stage biotechnology company that developed programmable epigenetic mRNA medicines using its proprietary Omega Platform and OMERs technology to treat oncology and rare genetic disease patients; the company ceased operations in 2025.
- Company typePublic
- Founded2016
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Omega Therapeutics does
Omega Therapeutics was a Cambridge, Massachusetts-based, publicly traded clinical-stage biotechnology company (NASDAQ: OMGA) founded in 2016 that developed programmable epigenetic medicines. The company built its business around a proprietary platform called the Omega Platform, which uses mRNA-based Epigenetic Modular Effectors (OMERs) to control gene expression in a reversible manner without altering DNA. This mechanism was positioned as differentiated from CRISPR-based permanent gene editing and from conventional mRNA vaccines.
The company's pipeline included lead candidate OTX-2002 in Phase 1/2 development for hepatocellular carcinoma, OTX-TKI for solid tumors, and additional rare genetic disease programs that received FDA Orphan Drug and Breakthrough Therapy designations. Target therapeutic areas spanned oncology, regenerative medicine, and rare genetic diseases. Omega Therapeutics had no commercial products, no disclosed pricing, and no distribution channels; its business model was research and clinical development funded by equity capital rather than product revenue.
The company raised approximately $279.4 million in cumulative equity financing across venture and post-IPO rounds, with Flagship Pioneering as the founding and lead investor across multiple rounds and broad institutional participation in the 2021 Series C. Despite clinical progression and regulatory designations, the company shut down operations in 2025 amid challenging biotech market conditions, high development costs, and difficulty raising additional capital.
Omega Therapeutics firmographics
Firmographics- Name
- Omega Therapeutics
- Website
- https://omegatherapeutics.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Closed
- Headcount range
- 51–100 employees
- Short description
- Omega Therapeutics was a Cambridge-based clinical-stage biotechnology company that developed programmable epigenetic mRNA medicines using its proprietary Omega Platform and OMERs technology to treat oncology and rare genetic disease patients; the company ceased operations in 2025.
- Ownership category
- akta.pro rank
Omega Therapeutics industry classification
Industry- Product category
- Epigenetic Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
- akta.pro secondary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
Keywords
Where Omega Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Omega Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Omega Therapeutics product offering
Product offeringCore offering
Omega Therapeutics developed programmable epigenomic mRNA medicines using its proprietary Omega Platform and OMERs technology to enable reversible control of gene expression without altering DNA. Its pipeline focused on therapeutic candidates for hepatocellular carcinoma (OTX-2002), solid tumors (OTX-TKI), regenerative medicine, and rare genetic diseases.
Product overview
Omega Therapeutics developed a single unified platform architecture centered on its proprietary Omega Platform and OMERs technology, which enables programmable epigenome editing without permanent DNA alteration. The company's therapeutic portfolio included lead candidate OTX-2002 for hepatocellular carcinoma and OTX-TKI for solid tumors, all leveraging the same core platform technology to target oncology, regenerative medicine, and rare genetic diseases. Note: The company shut down in 2025 according to multiple sources.
Differentiator
Problem solved
Functional benefit
Products and services
- Omega Platform
- OMERs Technology (Omega Epigenetic Regulators)
- OTX-2002
- OTX-TKI
Quantifiable outcome
- Phase 1/2 clinical trials for OTX-2002 in hepatocellular carcinoma
- +1 more outcomes
Companies that use Omega Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
Omega Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Omega Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights3 records
Omega Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Beam Therapeutics: Beam Therapeutics is a broad incumbent in base editing, offering precision gene editing capabilities across oncology and rare disease indications overlapping with Omega's target segments.
- Editas Medicine: Editas Medicine is a broad incumbent in CRISPR-based gene editing and cell therapies, with clinical programs in oncology and rare genetic diseases that compete for the same therapeutic indications as Omega.
- Sangamo Therapeutics: Sangamo is a broad incumbent in genomic medicine with zinc finger nuclease-based gene regulation capabilities, operating across multiple disease areas with overlapping gene modulation applications.
- Intellia Therapeutics: Intellia is a broad incumbent in CRISPR/Cas9-based gene editing with clinical-stage assets across multiple indications, representing the dominant gene editing modality Omega's platform was differentiated against.
Emerging players
- Tessera Therapeutics: Tessera Therapeutics is an emerging player in gene writing technology, pursuing programmable genomic modifications that overlap conceptually with Omega's approach to controlling gene expression.
- Arcturus Therapeutics: Arcturus Therapeutics is an emerging player in mRNA therapeutics technology, sharing Omega's mRNA-based delivery modality but focused primarily on vaccines and protein replacement rather than epigenome editing.
- Prime Medicine: Prime Medicine is an emerging player in prime editing technology, offering a different precision gene editing modality that targets similar disease areas and competes for partnership and capital attention in the gene medicine space.
Direct peers
- Tune Therapeutics: Tune Therapeutics is a direct peer focused on epigenetic gene silencing and reprogramming, employing programmable approaches that closely mirror Omega's reversible epigenome editing strategy.
- Chroma Medicine: Chroma Medicine is a direct peer developing epigenetic editing therapeutics using a similar programmable approach to gene regulation without altering DNA sequence, directly competing in the same modality as Omega's OMERs platform.
Others
- Epicypher: Epicypher is an adjacent tools and reagents provider for chromatin and epigenomics research, supplying enabling technologies that support epigenome editing platforms including Omega's drug discovery efforts.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Omega Therapeutics social profiles
Digital presenceOmega Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omega Therapeutics leadership team
Management profileNumber of profiles
Omega Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omega Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omega Therapeutics
What does Omega Therapeutics do?
Omega Therapeutics developed programmable epigenomic mRNA medicines using its proprietary Omega Platform and OMERs technology to enable reversible control of gene expression without altering DNA. Its pipeline focused on therapeutic candidates for hepatocellular carcinoma (OTX-2002), solid tumors (OTX-TKI), regenerative medicine, and rare genetic diseases.
Is Omega Therapeutics a public or private company?
Omega Therapeutics is a public company. It is classified as public and is currently closed.
When was Omega Therapeutics founded?
Omega Therapeutics was founded in 2016. It employs 51 to 100 people.
Where is Omega Therapeutics based?
Omega Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Omega Therapeutics's main competitors?
Broad incumbents on record are Beam Therapeutics, Editas Medicine, Sangamo Therapeutics and Intellia Therapeutics. Emerging players are Tessera Therapeutics, Arcturus Therapeutics and Prime Medicine. Direct peers are Tune Therapeutics and Chroma Medicine. Epicypher is listed as an others.
Does Omega Therapeutics have an API?
No public API is recorded for Omega Therapeutics.
What industry is Omega Therapeutics in?
Omega Therapeutics's product category is Epigenetic Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 325414 and its SIC code is 2834.